Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07302971

Telemedicine-supported Management for Acute Ischemic Stroke

Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies.

This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Ischemic Stroke Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Xuanwu Hospital

Beijing, Beijing Municipality, 100053, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospital Inclusion Criteria:
  • Basic-level hospitals in China (Definition: Hospitals classified as secondary-level (Grade II) or below under China's Hospital Grading Management Standards, or hospitals located in counties/county-level cities).
  • Equipped with an emergency department and neurology ward capable of admitting stroke patients.
  • Equipped with CT and/or MRI capable of diagnosing AIS.
  • Equipped with intravenous thrombolytic drugs for acute ischemic stroke.
  • Patient Inclusion Criteria:
  • Age ≥ 18 years.
  • Diagnosed with acute ischemic stroke.
  • CT/MRI confirms absence of intracerebral hemorrhage.
  • Onset of stroke symptoms ≤ 4.5 hours.
  • pre-stroke mRS score ≤1.
  • Informed consent obtained from patient or their legal representative.

Exclusion criteria

  • Hospital Exclusion Criteria:
  • Admitting fewer than 10 patients with acute ischemic stroke per month.
  • Currently participating in other clinical trials that may interfere with this trial.
  • Patient Exclusion Criteria:
  • Presence of contraindications for intravenous thrombolysis according to AHA/ASA guidelines

Treatment and study plan

Telemedicine-Supported Management

Other

Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.

Primary outcomes

  1. Proportion of patients with mRS scores of 0-1

    Time frame: 90 days

Secondary outcomes

  1. Intravenous thrombolysis rate

    Time frame: 4.5 hours

  2. mRS score

    Time frame: 90 days

    Ranges from 0 to 6 points, with lower scores indicating better functional outcome.

  3. Door-to-(thrombolysis)needle-time

    Time frame: 4.5 hours

    The time calculation begins when the patient arrives at the hospital and ends upon receiving thrombolytic therapy. The theoretical range is 0 to 270 minutes.

  4. Rate of endovascular therapy receipt among eligible patients

    Time frame: 24 hours

Other outcomes

  1. Proportion of sICH

    Time frame: Within 36 hours of thrombolysis

    The time frame is within 36 hours after thrombolysis in patients. Symptomatic intracranial hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.

  2. Proportion of any type of ICH

    Time frame: Within 36 hours of thrombolysis

    The time frame is within 36 hours of thrombolysis administration. Any type of intracerebral hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.

  3. All-cause mortality rate

    Time frame: 90 days

Study contacts

Contact information is provided by the study sponsor or research team.

Chuanjie Wu

CONTACT

[email protected]

01083199439

Xunming Ji

CONTACT

[email protected]

01083198962

Sponsors and collaborators

Lead sponsor

Capital Medical University

Other

Registry information

Official study title

Telemedicine-supported Management of Acute Ischemic Stroke in the Basic-level Hospitals

Acronym: TOGETHER

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 24, 2025
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.